TNFRSF10A and breast cancer: The comparison of six cell lines of human breast cancer (SKBR3, MDA-MB-468, MCF7, MDA-MB-231, T47D, and BT474) treated with recombinant human TRAIL (rhTRAIL) and antibodies against death receptor 4 (DR4) and death receptor 5 (DR5) for the apoptotic response showed the loss of expression of DR4 and DR5 in some cell lines that accounted to their antibody resistance.